Corporate Banner
Satellite Banner
Metabolomics & Lipidomics
Scientific Community
Become a Member | Sign in
Home>News>This Article

GFT505 Reduces the Risk of Cardiovascular Events

Published: Friday, May 17, 2013
Last Updated: Thursday, May 16, 2013
Bookmark and Share
Treatment with GFT505 significantly reduces the level of “remnant cholesterol”.

GENFIT has announced that GFT505 reduces a new component of cardiovascular risk: the cholesterol contained in lipid particles other than LDL and HDL, also known as ‘remnant cholesterol’.

All the Phase II clinical studies performed to date have shown that GFT505 improves classical lipid risk factors. It lowers the level of LDL-cholesterol (‘bad cholesterol’), increases the level of HDL-cholesterol (“good cholesterol”), and lowers the level of non-HDL-cholesterol and triglycerides in the blood.

A recently published study (Varbo et al. J Am Coll Cardiol 2013; 61: 427-36) of more than 70,000 subjects shows that the level of cholesterol not contained in LDL or HDL particles, also known as ‘remnant cholesterol’, is directly and causally associated with an elevated risk of ischemic heart disease.

According to this study, subjects with increased levels of remnant cholesterol have a two- to three-fold greater risk of developing ischemic heart disease than subjects with low levels of remnant cholesterol.

The data from the Phase IIa studies, GFT505-209-4 in pre-diabetic patients and GFT505-210-5 in diabetic patients, have been analyzed.

This analysis demonstrates that treatment with GFT505 (80 mg/day) significantly reduces the level of “remnant cholesterol” in these two patient populations.

In the GFT505-209-4 study, the effect of GFT505 on measured remnant cholesterol was -24% (p=0.0046) compared to the placebo group after 28 days of treatment.

Consistently, after 3 months of treatment in diabetic patients (study GFT505-210-5), the effect of GFT505 on calculated remnant cholesterol compared to the placebo group was -46% (p=0.01).

Two experts commented these results.
Professor Gerald Watts (University of Western Australia) declared: “GFT505, when administered as monotherapy to patients with pre-diabetes or diabetes, leads to a significant fall in plasma triglyceride and triglyceride-rich lipoprotein remnants. The 10-15% reduction in non-HDL cholesterol could be clinically significant in terms of a proportional reduction in cardiovascular events in patients with the metabolic syndrome.”

Professor Bart Staels, University of Lille 2 and President of the Scientific Advisory Board, precised: “NAFLD/NASH is considered to be the hepatic complication of the metabolic syndrome. Overall, the results of large outcome trials show that statin treatment decreases the cardiovascular risk by only 30%, the remaining 70% representing a high residual cardiovascular risk. Given Varbo et al’s demonstration of the causal link between the level of remnant cholesterol and cardiovascular risk, the beneficial effects of GFT505 on remnant cholesterol further strengthen its cardioprotective profile.”

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,800+ scientific posters on ePosters
  • More than 4,000+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Scientific News
Gut Microbes Signal to the Brain When They're Full
Don't have room for dessert? The bacteria in your gut may be telling you something.
Turning up the Tap on Microbes Leads to Better Protein Patenting
Mining millions of proteins could become faster and easier with a new technique that may also transform the enzyme-catalyst industry, according to University of California, Davis, researchers.
Drug May Prevent Life-Threatening Muscle Loss in Advanced Cancers
New data describes how an experimental drug can stop life-threatening muscle wasting (cachexia) associated with advanced cancers and restore muscle health.
Cancer-Fighting Tomato Component Traced
The metabolic pathway associated with lycopene, the bioactive red pigment found in tomatoes, has been traced by researchers at the University of Illinois.
Circadian Clock Controls Insulin and Blood Sugar in Pancreas
Map of thousands of genes suggests new therapeutic targets for diabetes.
Cellular Stress Process Identified in Cardiovascular Disease
Combining the investigative tools of genetics, transcriptomics, epigenetics and metabolomics, a Duke Medicine research team has identified a new molecular pathway involved in heart attacks and death from heart disease.
Predicting Adverse Drug Reactions with Higher Confidence
A new integrated computational method helps predicting adverse drug reaction—which are often lethal—more reliably than with traditional computing methods.
A New Way to Starve Lung Cancer?
Metabolic alterations in lung cancer may open new avenues for treating the disease.
Evidence of How Incurable Cancer Develops
Researchers in the West Midlands have made a breakthrough in explaining how an incurable type of blood cancer develops from an often symptomless prior blood disorder.
Building a Better Liposome
Computational models suggest new design for nanoparticles used in targeted drug delivery.
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,800+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,000+ scientific videos